Heron Therapeutics | HRTX - Ordinary Share Capital


Heron Therapeutics reported $188.31M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
ALKERMES USD 168.03M 489K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amarin USD 20.81M 13K Dec/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 141.14M 564K Jun/2026
Eisai JPY 282.46M 345K Jun/2026
Emergent BioSolutions USD 100K 0 Jun/2023
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 218.28M 1.76M Jun/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 1.05M Jun/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Omeros USD 611K 17K Dec/2023
Pacira USD 39.82M 512K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Veracyte USD 80.39M 598K Sep/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026